Jae B. Kim

Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria

H. Bonkovsky, P. Stein, R. Desnick, 2019, The New England journal of medicine.

Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen

E. Hoorn, Jae B. Kim, A. Danser, 2019, Hypertension.

Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations

P. Marquis, Jessica R. Hungate, W. Querbes, 2018, The Patient - Patient-Centered Outcomes Research.

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Preliminary Phase 1/2 Study Results in Patients with PNH

A. Borodovsky, N. Najafian, Jae B. Kim, 2016 .

Renoprotective Effects of Small Interfering RNA Targeting Liver Angiotensinogen in Experimental Chronic Kidney Disease

E. Hoorn, M. C. Clahsen‐van Groningen, Jae B. Kim, 2021, Hypertension.

Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria

V. Goel, G. Robbie, Sagar Agarwal, 2020, Clinical pharmacology and therapeutics.

Abstract 14387: Dose-Related Reductions in Blood Pressure With a RNA Interference (RNAi) Therapeutic Targeting Angiotensinogen in Hypertensive Patients: Interim Results From a First-In-Human Phase 1 Study of ALN-AGT01

Akshay S. Desai, G. Bakris, Sagar Agarwal, 2020 .

Normal reference ranges for urinary δ‐aminolevulinic acid and porphobilinogen levels

G. Robbie, Sagar Agarwal, A. Simon, 2020, JIMD reports.

A3941 Long-lasting small interfering RNA targeting angiotensinogen induces a robust and durable antihypertensive effect

E. Hoorn, Jae B. Kim, M. Poglitsch, 2018, Journal of Hypertension.